Lung Cancer Trial, Recruiting NCT05537922 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05537922
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older
  • People whose general health and ability to carry out daily activities meets a certain level, as measured by a standard cancer research scale (confirm with trial site)
  • People who have been diagnosed with advanced non-small cell lung cancer (stage IIIB, IIIC, or stage IV), confirmed through laboratory testing of tissue samples
  • For the retrospective (past records) group: people who have already received at least one course of immunotherapy treatment (a maintenance therapy called Durvalumab is also permitted)
  • For the prospective (new participants) group: people for whom a doctor has determined that immunotherapy is the appropriate first treatment for their cancer
  • People who have cancer that has spread to the brain are permitted to join
  • For the retrospective group: people whose cancer involves specific genetic changes that may drive cancer growth are also permitted
  • For the prospective group: people who have signed and dated a consent form showing they have been informed about and understand all important aspects of the study before joining
  • For the prospective group: people for whom at least one preserved tissue sample is available for laboratory analysis

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • For the retrospective group: people for whom there is not enough basic treatment history information available
  • For the prospective group: people who have already received treatment for advanced-stage disease
  • People who are unavailable or unable to follow the required study procedures, including completing quality-of-life questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 022390 3647

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Registry
ClinicalTrials.gov
Start date
1 October 2022
Est. completion
1 October 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇬🇷 Greece 🇮🇱 Israel 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Response Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov